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CNS derived Extracellular Vesicles as
Biomarkers in Multiple Sclerosis
(MS)
By Anshel Kenkare, with advisor
Dr. Abdolmohamad Rostami (*)

Introduction
•
•

•

MS is a clinically heterogenous disease making it difficult to diagnose
arising from a demyelinating pathology
Initiating treatment of MS early has been shown to improve patient
outcomes and slow disease progression

This study aims to find biomarkers to categorize biological changes in MS
(through extracellular vesicles containing oligodendrocyte proteins) à
Earlier and more accurate clinical decision making!

Introduction
• Extracellular vesicles can help categorize
autoimmune disease
• The blood brain barrier is dysregulated in
Multiple Sclerosis

Introduction

Objectives
& Hypothesis
• Research Question
– How do the extracellular vesicles contents of
cerebrospinal fluid (CSF) and blood compare between
unmedicated patients diagnosed with MS and noninflammatory headache controls?

• Hypothesis
– There will be a greater number of extracellular
vesicles visible in the CSF and blood of unmedicated
MS patients compared to healthy controls.
Furthermore, vesicles in the unmedicated patients
with MS will show signs of immune dysregulation.
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Approach & Results
• Analysis
- 7 confirmed MS CSF samples and 10 Headache CSF
samples were received
- 3 non-confirmed MS patients à 1 radiologically isolated
syndrome and 2 patients with a high suspicion
- All of these patients provided blood samples

- 5 MS and Headache patients also provided blood

- Vesicles were visualized for each sample to confirm
presence and count is being conducted
- Metabolomic analysis is currently being conducted on
the samples and will be available March 15th

Initial Metabolomic Analysis

Conclusions
• Currently we are waiting on the majority of the data
– Initial data
• Suggests that EVs can provide inflammatory
markers better than isolated CSF
• Blood is most likely not as useful for categorizing
MS at its diagnostic phase
• Counted EV samples show increased EVs in control
samples à This is being further analyzed
– Complete Data
• Will be available in March

Backup Plan

Future Directions
•

Repeating the experiment on a larger sample size of frozen CSF to confirm the
results

•

We expect to find novel biomarkers that can show signs of damage in MS

– In future research, we would hope to sub stratify and look for changes in biomarkers
associated with progression in MS. This could be helpful as in MS progression, biological
pathology often arises before clinical symptom onset

•

We hope the new biomarkers determined will lead to more research into using
extracellular vesicles as diagnostic tools and hope the biomarkers will provide
further insight into the underlying pathology of MS

•

If data holds up for vesicle count being increased analyzing vesicular membrane
integrity may be a future avenue for investigation
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